HOME >> BIOLOGY >> NEWS
VCU research shows erectile dysfunction drug reduces death of heart cells in heart attack model

RICHMOND, Va. (Jan. 31, 2005) Virginia Commonwealth University researchers have shown that a widely used drug for treating erectile dysfunction, Viagra, reduces the death of heart cells under heart attack-like conditions in a laboratory model.

The results are a key finding that may help researchers develop a new treatment for patients with heart failure where the loss of cells is primarily due to cell suicide.

In the Journal of Biological Chemistry, published online Jan. 24, VCU researchers found that treatment with Viagra, generically known as sildenafil citrate, at clinically relevant concentrations produced therapeutic levels of nitric oxide (NO) in the heart cells of mice by increasing protein levels of two enzymes responsible for the synthesis of NO.

Employing a cellular model where heart attack-like conditions are simulated in a Petri dish, they demonstrated that NO produced from sildenafil inhibits cell death by stabilizing mitochondria, increasing the level of the anti-death protein, Bcl-2, and inhibiting caspase 3, the protein considered to be the ultimate weapon in cell suicide.

"This research has established a strong basis for the design of future studies targeted toward investigating the clinical effects of sildenafil on survival of heart muscle following a major heart attack," said Rakesh C. Kukreja, Ph.D., professor of medicine, physiology and biochemistry at VCU, and lead author of the study.

"In addition, these findings suggest that this drug may slow or possibly reverse the progressive loss of heart cells during chronic heart failure in patients with coronary artery disease," he said.

Researchers used heart cells prepared from genetically engineered mice that lack nitric oxide synthesizing enzymes. The model was particularly useful in studying the protective effect of sildenafil in heart muscle cells independent of any vascular effects or other types of cells, Kukreja said.

According to Kukr
'"/>

Contact: Sathya Achia-Abraham
sbachia@vcu.edu
804-828-1231
Virginia Commonwealth University
31-Jan-2005


Page: 1 2

Related biology news :

1. NIH gives $8M to University of Pittsburgh School of Medicine for myositis research
2. Saudi Arabias KAUST names WHOI first research partner
3. Multinational research: protecting ecology means understanding people, too
4. Newly created cancer stem cells could aid breast cancer research
5. Carnegie Mellons Peter Adams receives EPA research grant
6. Almac Diagnostics announces pioneering genetic research on ductal carcinoma in situ
7. Innovative tagging technique may help researchers better protect fish stocks
8. Penn researchers discover how key protein stops inflammation
9. UCF research links proteins, stem cells and potential Alzheimers treatment
10. ASU researchers partner with UOP to make biofuel for military jets a reality
11. Einstein researchers prototype vaccine could provide improved protection against tuberculosis

Post Your Comments:
(Date:12/11/2014)... 2014 Research and Markets ... ( http://www.researchandmarkets.com/research/9ql3kr/biometrics_market ) has announced the addition of ... report to their offering. One ... adoption of multimodal biometric systems. Multimodal biometric systems ... for verification and identification purposes. This helps to ...
(Date:12/10/2014)... , Dec. 9, 2014  Wake Forest Baptist Medical Center ... for its School of Medicine. Funding for this $50 ... campaign that will be publicly launched next summer. ... in the former 60 series R.J. Reynolds Tobacco Company ... Construction will begin immediately with plans to be ready ...
(Date:12/5/2014)... , Dec. 4, 2014  Tute Genomics, a ... $2.3 million in Series A1 funding led by UK-based ... also participated in the investment round. "We ... healthcare community adopts next-generation sequencing and seeks new approaches ... Reid Robison , MD MBA, and CEO of ...
Breaking Biology News(10 mins):Biometrics Market in India 2015-2019: Key Vendors are 3M Cogent, NEC, Safran and Suprema 2Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 2Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 3Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 4Tute Genomics Raises $2.3 Million to Scale Up Cloud-Based Genome Analytics and Accelerate Personalized Medicine 2Tute Genomics Raises $2.3 Million to Scale Up Cloud-Based Genome Analytics and Accelerate Personalized Medicine 3
(Date:12/17/2014)... (PRWEB) December 17, 2014 Gene ... that it has entered into a technology access ... (ADM) to apply DNA2.0’s proprietary protein engineering technology, ... process. , “We are extremely excited that the ... platform. This proprietary bioengineering technology has now ...
(Date:12/17/2014)... SOUTH SAN FRANCISCO, Calif. , Dec. 17, ... positive results of a Phase 2 study evaluating ... for the treatment of patients with severe, chronic ... the current standard of care, including topical steroids ... endpoint was percent change in Visual Analog Scale ...
(Date:12/15/2014)...  GlassesOff Inc. (OTCBB: GLSO) announced today the appointment ... director of the Company,s Board of Directors. ... its CEO until its acquisition by Stanley Black ... Recognized as the inventor of the first Wi-Fi-based Active ... -based RFID solutions focused on improving operational efficiency, safety ...
(Date:12/13/2014)... (PRWEB) December 12, 2014 Clarassance, a ... announced its new name: Therabron Therapeutics , Inc. ... and bronchioles (a type of structure in the lungs ... company’s mission to develop novel protein therapeutics for the ... directors decided to change the name to mark the ...
Breaking Biology Technology:ADM and DNA2.0 Enter Into Protein Engineering Technology Access and Service Agreement 2Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 2Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 3Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 4AeroScout Founder Joins GlassesOff's Board of Directors 2AeroScout Founder Joins GlassesOff's Board of Directors 3Maryland-based Biotech Company's Path Forward in Treating Respiratory Diseases Sparks Name Change 2
Cached News: